Published in final edited form as:

Urol Oncol. 2019 March ; 37(3): 209–218. doi:10.1016/j.urolonc.2018.09.009.

Current Controversies on the Role of Retroperitoneal Lymphadenectomy for Testicular Cancer

Roy Mano, M.D., Renzo DiNatale, M.D., and Joel Sheinfeld, M.D.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

Retroperitoneal lymph node dissection is an important component of the multimodal treatment which cures most patients diagnosed with testicular germ cell tumors. Considering the high cure rates achieved, research focus in recent years has been directed towards improving quality of life and decreasing long term treatment related sequelae. Consequently, the role of RPLND has evolved over the past three decades in both low-stage and advanced testicular cancer.

The use of RPLND in clinically stage I and low volume stage II disease may offer the advantages of treating retroperitoneal teratoma which is present in 15% - 20% of patients, avoiding chemotherapy and reducing the need for frequent imaging during follow-up. Similarly, ongoing studies are evaluating the safety and effectiveness of RPLND for the treatment of early stage seminoma to avoid the long-term effects of chemotherapy and radiotherapy. RPLND is traditionally used for the treatment of residual masses > 1 cm after completion of chemotherapy. Its role in subcentimeter residual masses remains somewhat controversial given the fact that 25% - 30% of these patients are found to harbor either teratoma or viable non-teratomatous GCT. The presence of teratoma increases the probability of teratoma in metastatic sites.

Modified unilateral templates were developed based on early mapping studies with the aim of preserving antegrade ejaculation. Recent data suggests initial mapping studies underestimated the risk of contralateral retroperitoneal metastases which may reach 32%. Furthermore, antegrade ejaculation may be preserved in > 95% of patients undergoing bilateral nerve sparing primary RPLND and > 80% undergoing nerve-sparing PC-RPLND, which, in our view is the more prudent oncologic approach.

Recently, multiple series have demonstrated the safety and short-term efficacy of minimally invasive RPLND; however, larger studies with prolonged follow-up are required to validate the long-term oncologic efficacy of newer techniques.

Correspondence: Joel Sheinfeld, M.D., Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology, Deputy Chief, Urology Service Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA, Tel: +1 646 422 4311, Fax: +1 212 988 0760, sheinfejm@mskcc.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest and Disclosure Statement
None of the authors have anything to disclose.

Keywords

Testicular germ cell tumors; retroperitoneal lymph node dissection; post-chemotherapy surgery; minimally invasive surgery

Introduction

Retroperitoneal lymph node dissection (RPLND) is an essential part of the multimodal treatment of testicular cancer and contributes to the 95% overall cure rate.[1, 2] Historically, in the absence of effective chemotherapy, surgery was the best option for obtaining a durable remission.[3] The discovery of cisplatin in 1965 has revolutionized the treatment of testicular cancer, and has resulted in multiple controversies regarding the optimal integration of surgery in the treatment of patients with testicular germ cell tumors (GCT).[1]

Surgery has an established role for the treatment of post-chemotherapy residual masses in patients with non-seminomatous germ cell tumors (NSGCT) and select patients with seminoma.[4] However, the role of RPLND as the primary treatment of stage I and stage IIA/IIB NSGCT and for the management of patients with complete serological and radiographic response following chemotherapy remains controversial. Recently, there has been growing interest in the role of primary RPLND for the treatment of early stage seminoma.

Originally, RPLND performed in select centers included the resection of all nodal tissue surrounding the aorta and vena-cava extending cranially to the suprahilic region and caudally to the interiliac region. With the aim of decreasing surgical morbidity and preserving antegrade ejaculation, modified templates and subsequently, nerve sparing techniques were developed.[3] These changes have resulted in controversy regarding the appropriate limits of surgery.

Recently, multiple reports of minimally invasive RPLND have been published suggesting similar short- and intermediate-term results. However, it is still unknown whether these techniques will provide comparable long-term oncologic outcome.

In this seminar article, we will discuss current controversies associated with RPLND, and provide data delineating its evolving role in the treatment of testicular GCTs.

The Role of Primary RPLND for Non-seminoma Germ Cell Tumors (NSGCT)

Clinical Stage I

Treatment options for clinical stage I NSGCT include active surveillance, chemotherapy and RPLND, all of which obtain a long term overall survival nearing 100%. Occult metastatic disease is present in 20% - 30% of patients; thus, 70% - 80% are cured by orchiectomy alone.[5–8] A recent study reported the excellent outcome of active surveillance for clinical stage I NSGCT with an overall relapse rate of 19% at a median follow-up of 62 months (range, 1–277 months), and a 5-year disease specific survival of 99.4%.[9] The high rate of patients who do not require additional treatment following orchiectomy, and the morbidity

associated with RPLND and/or chemotherapy, raise appropriate concerns regarding their role in this setting.

Numerous studies have identified risk factors for occult retroperitoneal metastases which include percentage of embryonal carcinoma in the primary tumor and presence of vascular invasion, a combination of which predicted either pathologic stage II or relapse on surveillance in 46.5% - 88% of clinical stage I patients.[5–9] The presence of these risk factors may therefore identify patients who will benefit from additional treatment following orchiectomy.

A randomized phase III trial comparing the outcome of primary RPLND versus one course of BEP for the treatment of clinical stage I NSGCT sought to address the issue of optimal treatment for patients not undergoing active surveillance. The 2-year recurrence free survival rate was 99.5% for chemotherapy and 91.9% for surgery with a significant hazard ratio of 7.94 (95% CI 1.81–34.48), supporting the use of one course of BEP over RPLND in the community setting.[10] While the exceedingly high recurrence free survival rate following one course of BEP standardized this chemotherapy regimen as a treatment option for stage I NSGCT, this trial was criticized for multiple reasons including the use of unilateral RPLND templates which likely contributed to the relatively high surgical failure rate within the retroperitoneum and scrotum. Furthermore, as a multi-institutional study, it was performed by 61 centers with few procedures performed by most surgeons. Higher volume centers within this study have previously reported retroperitoneal relapse rates lower than 1%. In addition, the relatively short follow-up period of the study (median of 4.7 years), was insufficient to capture late relapses and relapses caused by slow-growing NSGCT and growing teratomas.[11]

Advantages of performing RPLND for the treatment of clinical stage I NSGCT include treatment of retroperitoneal teratoma which is chemo-refractory, present in 15% of patients with occult metastases, and amendable only to surgical treatment.[12, 13] Patients are able to avoid chemotherapy and its associated long term morbidity in more than 80% of cases (Table 1).[7, 10, 12–14] Furthermore, the rate of retroperitoneal recurrences following a complete bilateral template is less than 1%, therefore we do not use frequent imaging of the abdomen during follow-up.[13, 15, 16]

It is our current practice to perform active surveillance for patients with Stage I NSGCT who are at low risk for occult retroperitoneal metastases. For patients that are at high risk, especially in the presence of teratoma or yolk sac tumor in the primary lesion, we offer primary RPLND as a treatment option considering the advantages noted above.

Clinical Stage IS

Clinical stage IS NSGCT is defined as persistently elevated serum tumor markers (STMs) after orchiectomy in the absence of radiographic evidence of metastatic disease. Historically, these patients were treated with RPLND however, several studies have clearly demonstrated that most patients with clinical stage IS have occult systemic metastases, reflected by a very high failure rate following surgery, and should therefore be treated initially with IGCCCG risk-appropriate chemotherapy.[4, 17, 18]

Clinical Stage IIA and IIB

Treatment options for patients with clinical stage IIA and small unifocal (<3cm) IIB NSGCT include RPLND with adjuvant chemotherapy in select cases, or induction chemotherapy with or without PC- RPLND. Possible advantages of RPLND as a primary treatment are similar to those in stage I disease and include accurate staging of the disease, the treatment of teratoma which is present in approximately 20% of patients,[19, 20] and the avoidance of chemotherapy in 13% - 35% of patients who have node negative disease.[20–22] Although no randomized trial exists comparing the two approaches in this setting, there are two non-randomized studies.[20, 22] Weissbach et al. performed a prospective multicenter trial comparing 109 patients who received RPLND with 2 cycles of adjuvant chemotherapy with 78 patients who were treated with 3–4 cycles of primary chemotherapy. With a median follow-up of 36 months, 7% of patients receiving primary RPLND, and 11% of patients receiving primary chemotherapy suffered a disease relapse. The authors concluded that primary RPLND should be considered in patients with clinical stage IIA/ IIB NSGCT since fewer cycles of chemotherapy, and consequently a lower rate of chemotherapy induced complications, were required when RPLND was used as the primary treatment. Furthermore, surgery in the primary setting was associated with fewer complications compared to the PC-RPLND.[22] In a non-randomized comparison by Stephenson et al., 252 patients with clinical stage IIA and IIB NSGCT were treated with primary RPLND (n=136) or induction chemotherapy with PC-RPLND (n=116). When analyzed by primary treatment intervention, induction chemotherapy followed by PC-RPLND was associated with a significantly improved 5-year recurrence free survival compared to primary RPLND (98% vs. 79%, $P<0.001$, respectively). However, 5-year cancer specific survival were not significantly different (100% vs. 98%, $P=0.3$), and patients treated with primary RPLND received fewer chemotherapy cycles, 51% of whom avoided chemotherapy altogether (Table 1).[20]

Currently, most patients with bulky retroperitoneal (>3cm) disease and any patient with persistently elevated STMs are treated with IGCCCG risk-appropriate induction chemotherapy. Excluding patients with elevated post-orchietomy STMs or clinical stage IIB disease from primary RPLND significantly increased the 4-year progression free survival from 83% to 96%.[13] Furthermore, patients with teratoma in their primary tumor have a significantly higher risk of teratoma in their retroperitoneal nodes. These patients may benefit from primary RPLND considering the higher tendency for an incomplete response to primary chemotherapy.[19, 23, 24]

Primary RPLND as an Emerging Treatment for Early Stage Seminoma

RPLND is traditionally reserved for the treatment of NSGCT, and its current utilization for seminoma is limited mostly to large post-chemotherapy residual masses.[25] However, the long-term side effects of radiotherapy and chemotherapy, each of which is associated with an elevated risk of cardiovascular disease and secondary malignancies (particularly if both are required) resulting in an increased mortality, has led to growing interest in the use of RPLND for the treatment of earlier stage seminoma.[26, 27]

Three retrospective reports support the efficacy of primary RPLND in the treatment of seminoma with low volume retroperitoneal disease (Table 1).[28–30] In an early report, Warszawski et al. treated 63 patients with stage I/II seminoma with primary RPLND (45 stage I, 7 stage IIA and 11 stage IIB/C), which was the preferred treatment for seminoma in their institution up until the year 1985. With a median follow-up of 79 months, recurrence rates were 7% for stage I disease, all of which were outside the RPLND template. There were no relapses for patients with stage IIA disease. However, a 55% infield recurrence was reported for patients with stage IIB/IIC disease.[28] Two more recent retrospective reports evaluated the use of primary RPLND for seminoma in small cohorts of patients.[29, 30] Mezvrishvili et al. reported of 14 patients with pure seminoma who underwent modified template RPLND including 10 stage I patients at a high risk for disease relapse (primary tumor > 6cm), and 4 patients with clinical stage IIA. No adjuvant treatment was given and the patients remained free of disease at a follow-up of 56 months.[29] Hu et al. reported of 4 pure seminoma patients with isolated, low volume, retroperitoneal disease (3 stage IIA and 1 stage IIB) who were treated with modified template RPLND. No patient experienced disease recurrence with a mean follow-up of 25 months.[30] Despite the concern of the desmoplastic reaction associated with seminoma, both studies reported a minimal number of minor complications, and all patients maintained antegrade ejaculation.[29, 30] These studies suggest primary RPLND may be safe as the initial treatment of stage I and stage IIA seminoma with minimal side effects, and acceptable short-term oncologic outcomes.

Recently, two phase II, single arm, trials evaluating the outcome of RPLND without adjuvant treatment for low stage seminoma were initiated.[31, 32] The SEMS trial (NCT02537548), an American multi-institutional trial, aims to enroll 46 patients with isolated retroperitoneal disease, 1–3cm in size, or stage I disease with an isolated retroperitoneal relapse within 3 years.[31] The PRIMETEST trial (NCT02797626), a single center trial from Germany, aims to enroll 30 patients, and will include patients with an initial clinical stage IIA/IIB disease, and patients with recurrent disease after surveillance for clinical stage I who may have received one dose of carboplatin after orchiectomy. The patients will undergo a modified template RPLND with ipsilateral nerve-sparing when feasible using an open, laparoscopic or robotic-assisted approach.[32] The primary outcome for both studies will be recurrence free survival at either 2 or 3 years after RPLND, and secondary outcomes will include short- and long-term complication rates, quality of life, recurrence free survival at 5 years and overall survival.[31, 32] Both studies are currently recruiting and will be completed by 2021. While these studies may assist in clarifying the role of primary RPLND in this patient cohort, a potential concern is the use of modified templates.

We use RPLND within the setting of seminoma for the treatment of residual disease following chemotherapy. While the use of primary RPLND for low volume stage II seminoma may be promising, it is not a standardized treatment and is not our current practice.

Post-chemotherapy RPLND for patients with a complete response

There is a consensus regarding the importance of RPLND when treating NSGCT patients with post-chemotherapy residual masses larger than 1cm.[4] This approach is supported by the substantial rate of teratoma (39% - 42%) and viable malignancies (11% - 17%) in resected specimens.[33–35] Teratoma is chemo-resistant, and if left unresected has the potential for rapid growth, malignant transformation and late relapse.[36] When completely resected, the 5-year overall survival of patients with viable non teratomatous GCT following PC-RPLND is 72%. Durable remission rates are lower after chemotherapy if residual or relapsing disease was not completely resected.[37]

The role of PC-RPLND in patients who achieve complete radiographic and serologic response is controversial. The rates of viable GCT and teratoma in patients with nodes 10mm range from 20% - 35%. A meta-analysis of 588 men who underwent PC-RPLND for a sub-centimeter residual mass reported pooled estimates of 71% necrosis, 24% teratoma, and 4% viable GCT in the resected specimen.[38] Several studies evaluated the outcome of active surveillance for men achieving complete remission after chemotherapy for NSGCT.[38–40] Ehrlich et al. reported the study with the longest follow-up. A total of 141 patients who achieved complete remission were followed for a median time of 15.5 years. Twelve patients (8.5%) relapsed at a median time of 11 months from completion of chemotherapy, 6 of which recurred within the retroperitoneum. A total of 4 patients died of their disease 2 of which had a retroperitoneal recurrence. Estimated 15-year recurrence free survival rates were 95% for good-risk patients and 73% for intermediate- or poor-risk patients ($P = .001$).[39] Kollmannsberger et al. evaluated 161 patients who achieved complete response following chemotherapy. At a median follow-up of 52 months, 10 patients (6%) relapsed all of whom initially presented with IGCCCG good risk disease. All 10 remained disease free at a median follow-up of 64 months since recurrence.[40] A similar overall relapse rate of 6.4% and a retroperitoneal-only relapse rate of 2.1% with a median follow-up of 5.4 years were reported by Ravi et al.[38] The low relapse rates of 6% - 8.5% may favor the use of active surveillance in patients with a complete radiographic response to chemotherapy; however, a subset of patients may require avoidable second-line chemotherapy and suffer from the potential adverse outcome of unresected teratoma and/or late relapse. A properly performed nerve sparing bilateral RPLND is associated with a low rate of anejaculation, and a <1% rate of infield RP recurrence, eliminating the need for frequent CT scans during follow-up with their associated radiation exposure. While MRI may be a comparable alternative to CT in identifying involved lymph nodes without the associated radiation exposure; this advantage is limited to experienced users. Furthermore, both modalities may underestimate positive lesion especially in nodes <2 cm.[41, 42] Although the follow up for the latter two studies (Kollmannsberger et al. and Ravi et al.) is relatively short, the data suggests that IGCCCG good-risk patients, and those without teratoma in their primary tumor, who are at a lower risk for metastatic teratoma appear to be at lower risk for relapse.[43]

Desperation RPLND

Patients with chemo-refractory tumors who progress despite first- and second-line chemotherapy have a poor prognosis. Treatment options for these patients include third line systemic therapies or, for select patients, desperation RPLND. Suitable patients for desperation RPLND are those with slowly rising STMs and a limited volume of residual disease amenable to surgical resection.[44]

Few studies evaluated the outcome of desperation surgery in this setting.[45–47] Histological findings at the time of resection were viable GCT in 76% of cases and teratoma or fibrosis in 24%.[47] Postoperatively, 47% - 60% of patients had normalization of their STMs.[47] At a median follow-up of 57 – 74 months 37% - 57% of patients were alive without evidence of disease.[45–47] Significant predictors of a poor outcome included increasing serum HCG and AFP levels, redo RPLND, and germ cell cancer in the surgical specimen.[47]

These findings suggest that despite the overall poor outcome of desperation RPLND, it has a crucial role and can be the only way to achieve cure in this select group of patients.

Surgical Complications and Modified Template RPLND

Complication rates in early RPLND series ranged from 30% - 36%, with major complications occurring in 12% - 19% of patients.[48, 49] These bilateral templates often extended into the supra-hilar region, and resulted in nearly uniform retrograde ejaculation. [50]

In an attempt to reduce the rates of retrograde ejaculation, and using mapping studies to define the lymphatic spread of testicular cancer, several investigators developed modified unilateral templates which were used in a select group of patients in both the primary and post-chemotherapy setting (Figures 1, 2).[14, 15, 51–53] Donohue et al. evaluated the use of modified templates in a large cohort of patients with clinical stage I NSGCT treated with a primary RPLND. Overall relapse rates were not significantly different between patients who were treated with a modified unilateral template and a bilateral template (15%–18% compared to 13% respectively), and all relapses occurred outside the retroperitoneum. The ejaculation rate of patients who underwent unilateral modified template resection with prospective nerve sparing was very high approaching 98% of patients.[15] Beck et al. evaluated the role of modified templates in a highly select subset of patients who underwent PC-RPLND for low volume tumors limited to the ipsilateral primary landing zone whose STMs normalized after cisplatin based chemotherapy. With a median follow-up of 32 months, the estimated 2- and 5-year disease free survival rates were 95%. Four patients relapsed at a median of 8 months, all of which were outside the boundaries of a bilateral dissection.[51] In a follow-up study with a median follow-up of 125 months, the estimated 5- and 10- year recurrence free survival rates were 93% and 92%, respectively and the overall survival rate was 99% at 10 years. A total of 7 patients developed recurrent disease at a median time of 11 months, all of which occurred outside the boundaries of a full bilateral template RPLND.[52]

A better understanding of the retroperitoneal neuroanatomy led to the development of the nerve-sparing RPLND. Jewett et al. and Donohue et al. both reported series of patients who underwent bilateral nerve-sparing RPLND. In these series, ejaculation was preserved in 90% - 100% of patients, and recurrence was observed in 5% of patients in one series, all of whom had node positive disease and did not receive adjuvant chemotherapy.[54, 55]

When retrospectively comparing the two surgical approaches, an early study reported a lower complication rate associated with the modified unilateral procedure (9.4%) compared to a full bilateral dissection (19.3%).[53] Other studies did not show a difference in complication rates between unilateral and bilateral nerve sparing RPLND, however the type of complications differed between the two.[16]

Recent data has shown that the mapping studies supporting modified templates underestimated the extent of retroperitoneal metastases, and that the use of modified templates unnecessarily risks incomplete resection of contralateral metastasis. The reasons mapping studies underestimated the incidence of retroperitoneal metastases include lack of follow-up and the liberal use of postoperative chemotherapy.[56, 57] In the post-chemotherapy setting 7% - 32% of patients had evidence of extra-template retroperitoneal disease, depending on the boundaries of the modified template. Moreover, when using the Testicular Tumor Study Group templates, up to 26% of patients had extra template disease within the retroperitoneum despite having low volume post-chemotherapy retroperitoneal masses, less than 2cm in size.[57]

Given the concerns regarding the early mapping studies which were used to support modified templates, the comparable overall complication rates in contemporary reports, and high rates of antegrade ejaculation achieved by both nerve-sparing and modified templates, the more prudent oncologic approach, in our view, is a bilateral template performed in an experienced center, particularly in the post-chemotherapy setting.

Minimally invasive RPLND

The laparoscopic approach for RPLND was initially described in 1992, and introduced as a staging procedure.[58] Initial series included small cohorts of 6–29 patients with clinical stage I NSGCT. Perioperative complication rates ranged from 8%–47% and conversion rates ranged from 6%–13%. Six to 63% of patients had positive nodes and all were treated with chemotherapy.[58, 59] Cresswell et al. reported a series of 87 patients with clinical stage I GCT whom underwent laparoscopic modified template RPLND, with the goal of pathological staging. A quarter of the patient were diagnosed with lymph node involvement and treated with 2 cycles of BEP. With a median follow-up of 84 months, 9% of patients with pathological stage I disease who did not receive chemotherapy relapsed, including 2 retroperitoneal recurrences outside the modified template, and one port site metastasis.[60] The technical difficulty associated with the procedure, and its initial diagnostic intent precluded wide applicability.

More recently, several investigators have reported the use of minimally invasive surgery with a curative intent in the pre- and post-chemotherapy setting (Table 2).[61–63] In a single

center study, 91 patients with clinical stage I NSGCT underwent extended template laparoscopic RPLND. Twenty-one patients had pN1 disease and 7 had pN2. Adjuvant chemotherapy was given to 14/21 pN1 patients and all pN2 patients. With a median follow-up of 38 months, none of the patients with node positive disease recurred; however, 8% of patients with pN0 disease relapsed, including in the scrotum and the corpora.[61] The largest series of laparoscopic RPLND included 221 patients treated with a unilateral template for clinical stage I NSGCT. Twenty-nine patients (13%) had positive nodes, 7 of whom received adjuvant chemotherapy. With a median follow-up of 39 months, 6% of the patients relapsed, including 4% of pN0 patients and 27% of pN1 patients who did not receive chemotherapy. Over a third of the relapses occurred within the retroperitoneum.[62] Steiner et al. reported the long-term outcome of laparoscopic PC-RPLND for clinical stage II disease in a single center study. Patients with bulky disease (large tumors encasing vena cava, aorta, or renal vessels) after chemotherapy were not approached laparoscopically. A total of 71 patients underwent unilateral resection and 29 patients underwent bilateral resection. One patient with uncontrollable bleeding required open conversion. With a median follow-up of 59 months, one patient with a stage IIC disease managed by unilateral RPLND recurred within the retroperitoneum.[63] All three studies conclude that the present data supports the oncologic efficacy of laparoscopic RPLND. However, the findings are limited by a relatively short follow-up time, the common use of unilateral templates and the liberal use of adjuvant chemotherapy regardless of nodal volume of disease.

Robotic RPLND, initially described in the year 2006, is an additional approach for minimally invasive RPLND.[64] Multiple small cohorts with 3–47 patients suggest that robotic RPLND may be safely performed with a low complication rate and short hospital stay.[64] The largest series of primary robotic RPLND included 47 patients with clinical stage I-IIA NSGCT operated in multiple institutions. Modified unilateral templates were used in 96% of patients. Four percent of patients had intra-operative complications including one case of aortic injury which required conversion to open surgery; and 9% had an early post-operative complication. Five of 8 patients with node positive disease received adjuvant chemotherapy, and one patient had a pelvic recurrence at a median follow-up of 16 months (Table 2).[65] While most series used a modified unilateral template, Stepanian et. al described a supine robotic approach used for bilateral template dissection; however, its use was limited to patients with a positive lymph node on frozen section or in the post-chemotherapy setting.[66] Cheney et al. compared the surgical characteristics of robotic primary RPLND and robotic PC-RPLND performed in patients with residual retroperitoneal lymphadenopathy or persistently elevated tumor markers after primary chemotherapy. PC-RPLND was associated with higher complication and open conversion rates and longer operative times, however, the estimated blood loss, lymph node yield and length of hospital stay were not significantly different.[67]

While overall complication rates of MIS RPLND are comparable to those of open RPLND, several series suggest a higher rate of chylous ascites which appears in up to 6.6% of patients who undergo laparoscopic RPLND and 4.3% of patients who undergo robotic RPLND.[65] However, recent laparoscopic series had a relatively low rate of chylous ascites similar to that of open RPLND, possibly due to improved surgical technique and instrumentation associate with these series.[61–63]

Few studies have compared the different treatment approaches.[68, 69] When comparing open PC-RPLND (n=24) and laparoscopic PC-RPLND (n=43), median operative time and major complication rates did not differ between the two approaches. Median post-operative hospital stay and duration of drainage was significantly shorter following laparoscopic PC-RPLND. Tumor recurrence rates were 8.6% for laparoscopic PC-RPLND and 14.2% for open PC-RPLND with mean disease-free survival rates of 76.6 months and 89.2 months, respectively. There was no significant difference in overall survival. These findings are limited due to the substantial selection bias as apparent by the median residual tumor size (2.2cm for laparoscopic PC-RPLND and 6.8cm for open PC-RPLND, p=0.002) and the reported outcomes.[68] A small series comparing laparoscopic and robotic RPLND using a modified template, has shown comparative intra- and peri-operative outcomes and failed to show any benefit to the robotic approach over the standard laparoscopic approach to justify the additional cost associated with this technique.[69]

Concerns regarding the minimally invasive approach include the extent and thoroughness of dissection, the possible deleterious effects of the pneumoperitoneum with possible diffuse carcinomatosis, and the possibility of uncontrollable large vessel injury.[61] Furthermore, while both procedures were found to be safe, with low complication rates and short hospital stay, data regarding the oncologic outcome are limited by the small cohort size, short-term follow-up, the common use of modified templates and the liberal use of adjuvant chemotherapy which is often avoided in pN1, marker negative disease. Most importantly, considering the impressive cure rates associated with conventional RPLND, based on large patient cohorts with long-term follow-up, it is necessary to validate the long-term oncologic efficacy of newer techniques within a trial setting.[70]

Summary

RPLND remains a critical component in the effective multimodal management of patients with testicular cancer. Its role has evolved significantly over the past three decades in both low-stage and advanced testicular cancer. RPLND is both a diagnostic and therapeutic procedure, but it must always be done with therapeutic intent, and not rely on effective cisplatin-based chemotherapy to compensate for suboptimal initial surgery. Studies addressing late relapse, re-operative surgery and contemporary mapping studies all suggest that a subset of patients undergoing either a primary or PC-RPLND will have unresected extra-template disease if modified templates are utilized. Early mapping studies, which provided the basis for these modified templates have significant limitations and the need for re-operative surgery is an adverse and independent prognostic variable. In our view, when an RPLND is deemed to be an appropriate component in the management of a patient with testicular cancer, a bilateral nerve-sparing template is the most oncologically prudent approach and achieves comparable functional outcomes in high volume centers.

Acknowledgments

Funding

This work was supported by The Richard Capri Foundation and The Sidney Kimmel Center for Prostate and Urologic Cancers.

This work was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

References

- [1]. Hanna NH, Einhorn LH. Testicular cancer--discoveries and updates. *The New England journal of medicine*. 2014;371:2005–16. [PubMed: 25409373]
- [2]. Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C. Testicular germ cell tumours. *Lancet*. 2016;387:1762–74. [PubMed: 26651223]
- [3]. Masterson TA, Cary C, Rice KR, Foster RS. The Evolution and Technique of Nerve-Sparing Retroperitoneal Lymphadenectomy. *The Urologic clinics of North America*. 2015;42:311–20. [PubMed: 26216818]
- [4]. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Testicular Cancer, Version 2.2015. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2015;13:772–99. [PubMed: 26085393]
- [5]. Albers P, Siener R, Kliesch S, Weissbach L, Kroke S, Sparwasser C, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21:1505–12. [PubMed: 12697874]
- [6]. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. *Cancer*. 1998;83:1002–11. [PubMed: 9731905]
- [7]. Hermans BP, Sweeney CJ, Foster RS, Einhorn LE, Donohue JP. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. *The Journal of urology*. 2000;163:1721–4. [PubMed: 10799168]
- [8]. Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1990;8:509–18. [PubMed: 1689773]
- [9]. Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2015;33:51–7. [PubMed: 25135991]
- [10]. Albers P, Siener R, Kroke S, Schmelz HU, Dieckmann KP, Heidenreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008;26:2966–72. [PubMed: 18458040]
- [11]. Sheinfeld J, Motzer RJ. Stage I testicular cancer management and necessity for surgical expertise. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008;26:2934–6. [PubMed: 18458042]
- [12]. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrl R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. *British journal of urology*. 1993;71:326–35. [PubMed: 8386580]
- [13]. Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2005;23:2781–8. [PubMed: 15837993]
- [14]. Richie JP. Clinical stage I testicular cancer: the role of modified retroperitoneal lymphadenectomy. *The Journal of urology*. 1990;144:1160–3. [PubMed: 2172569]
- [15]. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrl R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. *The Journal of urology*. 1993;149:237–43. [PubMed: 8381190]

- [16]. Heidenreich A, Albers P, Hartmann M, Kliesch S, Kohrmann KU, Krege S, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. *The Journal of urology*. 2003;169:1710–4. [PubMed: 12686815]
- [17]. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. *The Journal of urology*. 1994;152:111–3; discussion 4. [PubMed: 7515445]
- [18]. Dash A, Carver BS, Stasi J, Bajorin DF, Motzer RJ, Bosl GJ, et al. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. *Cancer*. 2008;112:800–5. [PubMed: 18172902]
- [19]. Foster RS, Baniel J, Leibovitch I, Curran M, Bihrlé R, Rowland R, et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. *The Journal of urology*. 1996;155:1943–5. [PubMed: 8618293]
- [20]. Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25:5597–602. [PubMed: 18065732]
- [21]. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrlé R. Clinical stage B nonseminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. *European journal of cancer*. 1995;31A:1599–604. [PubMed: 7488408]
- [22]. Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. *European urology*. 2000;37:582–94. [PubMed: 10765098]
- [23]. Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, et al. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1987;5:906–11. [PubMed: 2438389]
- [24]. Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIB germ cell tumors with teratomatous elements. *Cancer*. 1996;78:480–6. [PubMed: 8697394]
- [25]. Patel HD, Joice GA, Schwen ZR, Semerjian A, Alam R, Srivastava A, et al. Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes. *World journal of urology*. 2018;36:73–8. [PubMed: 29026972]
- [26]. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2004;22:640–7. [PubMed: 14726503]
- [27]. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *Journal of the National Cancer Institute*. 2005;97:1354–65 [PubMed: 16174857]
- [28]. Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. *Scandinavian journal of urology and nephrology*. 1997;31:355–9. [PubMed: 9290165]
- [29]. Mezvishvili Z, Managadze L. Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma. *International urology and nephrology*. 2006;38:615–9. [PubMed: 17111085]
- [30]. Hu B, Shah S, Shojaei S, Daneshmand S. Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma. *Clinical genitourinary cancer*. 2015;13:e265–9. [PubMed: 25682512]
- [31]. Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma, <https://ClinicalTrials.gov/show/NCT02537548>; accessed 22 February 2018

- [32]. Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST), <https://ClinicalTrials.gov/show/NCT02797626>; accessed 22 February 2018
- [33]. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25:5603–8. [PubMed: 17998544]
- [34]. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, et al. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? *Cancer*. 2006;107:1503–10. [PubMed: 16944534]
- [35]. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt Koops H, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1995;13:1177–87. [PubMed: 7537801]
- [36]. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25:1033–7. [PubMed: 17261854]
- [37]. Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2008;19:259–64. [PubMed: 18042838]
- [38]. Ravi P, Gray KP, O'Donnell EK, Sweeney CJ. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2014;25:331–8. [PubMed: 24276027]
- [39]. Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2010;28:531–6. [PubMed: 20026808]
- [40]. Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2010;28:537–42. [PubMed: 20026807]
- [41]. Ellis JH, Bies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP. Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. *Journal of computer assisted tomography*. 1984;8:709–19. [PubMed: 6539790]
- [42]. Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband JE, Dearnaley DP, et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. *Clinical radiology*. 2009;64:362–7. [PubMed: 19264179]
- [43]. Bosl GJ, Motzer RJ. Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2010;28:519–21. [PubMed: 20026799]
- [44]. Carver BS. Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors. *The Urologic clinics of North America*. 2015;42:343–6. [PubMed: 26216821]
- [45]. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. *Urology*. 1994;43:74–80. [PubMed: 7506856]
- [46]. Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. *British journal of urology*. 1998;81:884–8. [PubMed: 9666776]

- [47]. Beck SD, Foster RS, Bihrlé R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2005;23:6149–56. [PubMed: 16135481]
- [48]. Sago AL, Ball TP, Novicki DE. Complications of retroperitoneal lymphadenectomy. *Urology*. 1979;13:241–3. [PubMed: 442335]
- [49]. Staubitz WJ, Early KS, Magoss IV, Murphy GP. Surgical management of testis tumor. *The Journal of urology*. 1974;111:205–9. [PubMed: 4810766]
- [50]. Large MC, Sheinfeld J, Eggener SE. Retroperitoneal lymph node dissection: reassessment of modified templates. *BJU international*. 2009;104:1369–75. [PubMed: 19840015]
- [51]. Beck SD, Foster RS, Bihrlé R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? *Cancer*. 2007;110:1235–40. [PubMed: 17665498]
- [52]. Cho JS, Kaimakiotis HZ, Cary C, Masterson TA, Beck S, Foster R. Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. *BJU international*. 2017;120:104–8. [PubMed: 28296054]
- [53]. Baniel J, Foster RS, Rowland RG, Bihrlé R, Donohue JP. Complications of primary retroperitoneal lymph node dissection. *The Journal of urology*. 1994;152:424–7. [PubMed: 8015086]
- [54]. Jewett MA, Kong YS, Goldberg SD, Sturgeon JF, Thomas GM, Alison RE, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. *The Journal of urology*. 1988;139:1220–4. [PubMed: 2836633]
- [55]. Donohue JP, Foster RS, Rowland RG, Bihrlé R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. *The Journal of urology*. 1990;144:287–91; discussion 91–2. [PubMed: 2165181]
- [56]. Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25:4365–9. [PubMed: 17906201]
- [57]. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. *The Journal of urology*. 2007;177:937–42; discussion 42–3. [PubMed: 17296380]
- [58]. Finelli A. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: long-term oncologic outcomes. *Current opinion in urology*. 2008;18:180–4. [PubMed: 18303540]
- [59]. Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. *European urology*. 2008;54:1004–15. [PubMed: 18722704]
- [60]. Cresswell J, Scheitlin W, Gozen A, Lenz E, Teber D, Rassweiler J. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience. *BJU international*. 2008;102:844–8. [PubMed: 18537954]
- [61]. Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. *The Journal of urology*. 2012;187:487–92. [PubMed: 22177913]
- [62]. Nicolai N, Tarabelloni N, Gasperoni F, Catanzaro M, Stagni S, Torelli T, et al. Laparoscopic Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. *The Journal of urology*. 2017.

- [63]. Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. *European urology*. 2013;63:1013–7. [PubMed: 23021090]
- [64]. Chalfin HJ, Ludwig W, Pierorazio PM, Allaf ME. Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes. *Current urology reports*. 2016;17:41. [PubMed: 26968421]
- [65]. Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, et al. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. *European urology*. 2017;71:476–82. [PubMed: 27234998]
- [66]. Stepanian S, Patel M, Porter J. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique. *European urology*. 2016;70:661–7. [PubMed: 27068395]
- [67]. Cheney SM, Andrews PE, Leibovich BC, Castle EP. Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. *BJU international*. 2015;115:114–20. [PubMed: 24825773]
- [68]. Busch J, Magheli A, Erber B, Friedersdorff F, Hoffmann I, Kempkensteffen C, et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis. *BMC urology*. 2012;12:15. [PubMed: 22651395]
- [69]. Harris KT, Gorin MA, Ball MW, Pierorazio PM, Allaf ME. A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. *BJU international*. 2015;116:920–3. [PubMed: 25781349]
- [70]. Sheinfeld J, Masterson TA. A Laparoscopic Approach is Best for Retroperitoneal Lymph Node Dissection: No. *The Journal of urology*. 2017;197:1384–6.

Highlights

- RPLND is a crucial component of the multimodal treatment for testicular cancer
- Primary RPLND for stage I-II NSGCT treats teratoma, and reduces use of chemotherapy
- The role of primary RPLND in early stage seminoma is currently evaluated
- Bilateral nerve-sparing RPLND preserves ejaculation with better RP control
- Long term oncological data for minimally invasive RPLND is currently lacking

Figure 1.

– Boundaries of full-template RPLND. The renal vessels form the superior boundary, the ureters form the lateral boundary, and the bifurcation of the iliac vessels forms the inferior boundary. IMA, inferior mesenteric artery; IVC, inferior vena cava; SMA, superior mesenteric artery. Obtained with permission from Thomas E. Keane, Sam D. Graham and Marc Goldstein, Glenn's Urologic Surgery 8th edition, Philadelphia: Wolters Kluwer, 2016.

Figure 2.

– Right and left modified templates for RPLND. Several side-specific modified templates for patients with low-stage NSGCT have been proposed, with each including ipsilateral lymph nodes inferior to the renal hilum extending to the bifurcation of the iliac arteries. Right-sided templates include the interaortocaval region, and both avoid dissection below the contralateral IMA. Obtained with permission from Thomas E. Keane, Sam D. Graham and Marc Goldstein, Glenn's Urologic Surgery 8th edition, Philadelphia: Wolters Kluwer, 2016.

Table 1

– Summary of articles evaluating the outcome of primary RPLND in different clinical stages of testicular germ cell tumors

Reference	No. Pts.	RPLND Template	Adjuvant Chemotherapy (%)	Follow-up (months)	Relapse rate (%)	Death rate (%)
Stage I NSGCT						
Richie et al. 1990[14]	85	Unilateral	15	38 (median)	6 PS I; 15 PS II	0
Donohue et al. 1993[12]	378 *	Bilateral and unilateral	13	71.3 (mean)	12 PS I; 34 PS II without Cx; 0 PS II with Cx	0.8
Hermans et al. 2000[7]	292	NA	12	46 (median)	10 PS I; 23 PS II without Cx; 0 PS II with Cx	0.3
Stephens on et al. 2005[13]	297	Bilateral and unilateral	15	59 (median)	6 PS I; 19 PS II	0
Albers et al. 2008[10]	173	Unilateral	18	56 (median)	9 Overall	0
Stage II NSGCT						
Donohue et al. 1995[21]	140 *	Bilateral and unilateral	42	132 (mean)	6 PS I; 37 PS II without Cx; 0 PS II with Cx	2
Weissbach et al. 2000[22]	109	Bilateral and unilateral	88	36 (median)	23 PS I; 5 PS II-III with Cx	0
Stephens on et al. 2007[20]	136	Bilateral and unilateral	49	63 (median)	21 overall at 5-year	2 at 5-year
Stage I-II Seminoma						
Warszawski et al. 1997[28]	45 CS I; 18 CSII	Bilateral	0	79 (median)	7 PS I, 33 PS II	8 at 5-years
Mezvrishvili et al. 2006[29]	IOCS I; 4 CS II	Unilateral	0	56 (mean)	0	0
Hu et al. 2015[30]	4CS II	Unilateral	0	25 (mean)	0	0

RPLND = retroperitoneal lymph node dissection; NSGCT = non-seminoma germ cell tumor; PS = pathologic stage; Cx = chemotherapy; NA = not available; CS = clinical stage

* Includes patients treated after 1979.

Table 2

– Summary of the main series evaluating the outcome of laparoscopic and robotic assisted laparoscopic retroperitoneal lymph node dissection

Reference	No. Pts.	Clinical Stage	PCRPLND	RPLND Template	Adjuvant Chemotherapy (%)	Followup (months)	Relapse rate (%)
Laparoscopic RPLND							
Cresswell et al. 2008[60]	87	I	No	Unilateral	24	84 (mean)	9 PS I; OPS II
Hyams et al. 2012[61]	91	I	No	Bilateral	23	38 (median)	8 PS I; OPS II with or without Cx
Steiner et al. 2013[63]	100	II	Yes	Unilateral and bilateral	2	59 (median)	1 Overall
Nicolai et al. 2017[62]	221	I	No	Unilateral	3	39 (median)	4 PS I; 27 PS II without Cx; 0 PS II with Cx
Robotic assisted laparoscopic RPLND							
Stepanian et al. 2016 [66]	19	I (H); II (6); III (2)	No (16); Yes (3)	Unilateral and bilateral	11	49 (median)	5 Overall
Pearce et al. 2017[65]	47	I (42); IIA(5)	No	Unilateral	11	16 (median)	2 Overall

RPLND = retroperitoneal lymph node dissection; PC-RPLND = post chemotherapy retroperitoneal lymph node dissection; PS = pathologic stage; Cx = chemotherapy